This interview discusses Little Green Pharma’s (ASX:LGP) record-breaking quarterly results for June 2024, highlighting a 12% increase in revenue and significant cash receipts. CEO Paul Long elaborates on the company’s growth drivers, including new product sales in Australia and Europe, and outlines their strategy to maintain market share and expand in emerging European markets.
More From The Market Online
Lunnon ramping up Lady Herial development after overcoming recent weather issues
Lunnon Metals has overcome recent weather issues and is preparing for the processing of the first…
- Colin Sandell-Hay
- 2 mins
- 01 April 2026 13:52 (AEDT)
Goldarc Resources secures strategic Kookynie tenement
GoldArc Resources has made a strategic acquisition to expand its Leonora South project footprint in Western…
- Colin Sandell-Hay
- 2 mins
- 01 April 2026 16:16 (AEDT)
Sun Silver kicks off four rig Maverick campaign
Sun Silver has mobilised four diamond core drill rigs as it accelerates drilling at the Maverick…
- Colin Sandell-Hay
- 2 mins
- 01 April 2026 15:23 (AEDT)
Viva, Ampol both trade red ahead of expected Albo fuel rationing presser
If you’re brave enough to have raised your neck to survey the land of Australia’s finance news ecosystem on Wednesday, you already know
- Jonathon Davidson
- 3 mins
- 01 April 2026 15:15 (AEDT)
